Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase

Science Translational Medicine

Volumn 4, Issue 123, 2012, Pages

  García, Mayra ^a   Cooper, Arik ^a   Shi, Wei ^a   Bornmann, William ^b   Carrion, Ricardo ^c   Kalman, Daniel ^d   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALANINE; IMATINIB; NILOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN VP40; SMALL INTERFERING RNA; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTIVIRUS AGENT; CORE PROTEIN; NUCLEOPROTEIN; NUCLEOPROTEIN VP40, EBOLA VIRUS; PYRIMIDINE DERIVATIVE; TYROSINE; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; BLEEDING; CELL CULTURE; CONTROLLED STUDY; DEATH; DRUG DESIGN; DRUG TARGETING; EBOLA VIRUS; FILOVIRUS; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOTENSION; LIFE CYCLE STAGE; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHOCK; VASCULAR DISEASE; VIRUS LIKE AGENT; VIRUS PATHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; CELL STRAIN HEK293; CERCOPITHECUS; CLASSIFICATION; CYTOPATHOGENIC EFFECT; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MUTATION; PATHOGENICITY; PHOSPHORYLATION; RNA INTERFERENCE; TIME; VERO CELL;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; EBOLAVIRUS; HEK293 CELLS; HUMANS; MUTATION; NUCLEOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TYROSINE; VERO CELLS; VIRAL CORE PROTEINS; VIRAL PROTEINS; VIRUS RELEASE; VIRUS REPLICATION;

EID: 84857693882     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003500     Document Type: Article

References (58)

1. Y. Huang, L. Xu, Y. Sun, G. J. Nabel, The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol. Cell 10, 307-316 (2002).
2. T. Noda, H. Ebihara, Y. Muramoto, K. Fujii, A. Takada, H. Sagara, J. H. Kim, H. Kida, H. Feldmann, Y. Kawaoka, Assembly and budding of Ebolavirus. PLoS Pathog. 2, e99 (2006).
3. W. Shi, Y. Huang, M. Sutton-Smith, B. Tissot, M. Panico, H. R. Morris, A. Dell, S. M. Haslam, J. Boyington, B. S. Graham, Z. Y. Yang, G. J. Nabel, A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J. Virol. 82, 6190-6199 (2008).
4. G. Ruthel, G. L. Demmin, G. Kallstrom, M. P. Javid, S. S. Badie, A. B. Will, T. Nelle, R. Schokman, T. L. Nguyen, J. H. Carra, S. Bavari, M. J. Aman, Association of Ebola virus matrix protein VP40 with microtubules. J. Virol. 79, 4709-4719 (2005).
5. E. A. Burton, R. Plattner, A. M. Pendergast, Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J. 22, 5471-5479 (2003).
6. A. Swimm, B. Bommarius, Y. Li, D. Cheng, P. Reeves, M. Sherman, D. Veach, W. Bornmann, D. Kalman, Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Mol. Biol. Cell 15, 3520-3529 (2004).
7. P. M. Reeves, B. Bommarius, S. Lebeis, S. McNulty, J. Christensen, A. Swimm, A. Chahroudi, R. Chavan, M. B. Feinberg, D. Veach, W. Bornmann, M. Sherman, D. Kalman, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat.Med. 11, 731-739 (2005).
8. A. I. Swimm, W. Bornmann, M. Jiang, M. J. Imperiale, A. E. Lukacher, D. Kalman, Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J. Virol. 84, 4243-4251 (2010).
9. P. M. Reeves, S. K. Smith, V. A. Olson, S. H. Thorne, W. Bornmann, I. K. Damon, D. Kalman, Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on Abl and Src family tyrosine kinases. J. Virol. 85, 21-31 (2011).
10. C. L. Sawyers, Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340 (1999).
11. J. M. Goldman, B. J. Druker, Chronic myeloid leukemia: Current treatment options. Blood 98, 2039-2042 (2001).
12. M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, R. B. Arlinghaus, T. Sun, H. Kantarjian, M. Beran, AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11, 4941-4947 (2005).
13. T. O'Hare, D. K. Walters, M. W. Deininger, B. J. Druker, AMN107: Tightening the grip of imatinib. Cancer Cell 7, 117-119 (2005).
14. E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, J. D. Griffin, AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769 (2006).
15. B. J. Druker, Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817 (2008).
16. J. M. Licata, R. F. Johnson, Z. Han, R. N. Harty, Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78, 7344-7351 (2004).
17. B. Bommarius, D. Maxwell, A. Swimm, S. Leung, A. Corbett, W. Bornmann, D. Kalman, Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation. Mol. Microbiol. 63, 1748-1768 (2007).
18. B. Hartlieb, W. Weissenhorn, Filovirus assembly and budding. Virology 344, 64-70 (2006).
19. R. N. Harty, M. E. Brown, G. Wang, J. Huibregtse, F. P. Hayes, A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding. Proc. Natl. Acad. Sci. U.S.A. 97, 13871-13876 (2000).
20. L. D. Jasenosky, Y. Kawaoka, Filovirus budding. Virus Res. 106, 181-188 (2004).
21. C. A. Zampieri, N. J. Sullivan, G. J. Nabel, Immunopathology of highly virulent pathogens: Insights from Ebola virus. Nat. Immunol. 8, 1159-1164 (2007).
22. T. Noda, H. Sagara, E. Suzuki, A. Takada, H. Kida, Y. Kawaoka, Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76, 4855-4865 (2002).
23. J. Timmins, G. Schoehn, S. Ricard-Blum, S. Scianimanico, T. Vernet, R. W. Ruigrok, W. Weissenhorn, Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J. Mol. Biol. 326, 493-502 (2003).
24. T. Hoenen, N. Biedenkopf, F. Zielecki, S. Jung, A. Groseth, H. Feldmann, S. Becker, Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J. Virol. 84, 7053-7063 (2010).
25. R. F. Johnson, P. Bell, R. N. Harty, Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol. J. 3, 31 (2006).
26. Y. Liu, L. Cocka, A. Okumura, Y. A. Zhang, J. O. Sunyer, R. N. Harty, Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. J. Virol. 84, 2294-2303 (2010).
27. J. M. Smith, B. J. Mayer, Abl: Mechanisms of regulation and activation. Front. Biosci. 7, d31-d42 (2002).
28. J. E. Dueber, B. J. Yeh, K. Chak, W. A. Lim, Reprogramming control of an allosteric signaling switch through modular recombination. Science 301, 1904-1908 (2003).
29. J. E. Dueber, B. J. Yeh, R. P. Bhattacharyya, W. A. Lim, Rewiring cell signaling: The logic and plasticity of eukaryotic protein circuitry. Curr. Opin. Struct. Biol. 14, 690-699 (2004).
30. M. Karplus, J. Kuriyan, Molecular dynamics and protein function. Proc. Natl. Acad. Sci. U.S.A. 102, 6679-6685 (2005).
31. A. Pardanani, A. Tefferi, Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931-1939 (2004).
32. F. J. Giles, M. O'Dwyer, R. Swords, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23, 1698-1707 (2009).
33. G. Neumann, H. Ebihara, A. Takada, T. Noda, D. Kobasa, L. D. Jasenosky, S. Watanabe, J. H. Kim, H. Feldmann, Y. Kawaoka, Ebola virus VP40 late domains are not essential for viral replication in cell culture. J. Virol. 79, 10300-10307 (2005).
34. J. Martin-Serrano, D. Perez-Caballero, P. D. Bieniasz, Context-dependent effects of L domains and ubiquitination on viral budding. J. Virol. 78, 5554-5563 (2004).
35. J. Yasuda, M. Nakao, Y. Kawaoka, H. Shida, Nedd4 regulates egress of Ebola virus-like particles from host cells. J. Virol. 77, 9987-9992 (2003).
36. S. L. Pelech, J. S. Sanghera, Mitogen-activated protein kinases: Versatile transducers for cell signaling. Trends Biochem. Sci. 17, 233-238 (1992).
37. O. Dolnik, L. Kolesnikova, S. Becker, Filoviruses: Interactions with the host cell. Cell. Mol. Life Sci. 65, 756-776 (2008).
38. L. H. Elliott, M. P. Kiley, J. B. McCormick, Descriptive analysis of Ebola virus proteins. Virology 147, 169-176 (1985).
39. S. Becker, S. Huppertz, H. D. Klenk, H. Feldmann, The nucleoprotein of Marburg virus is phosphorylated. J. Gen. Virol. 75 (Pt. 4), 809-818 (1994).
40. J. Modrof, C. Möritz, L. Kolesnikova, T. Konakova, B. Hartlieb, A. Randolf, E. Mühlberger, S. Becker, Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions. Virology 287, 171-182 (2001).
41. C. Sänger, E. Mühlberger, B. Lötfering, H. D. Klenk, S. Becker, The Marburg virus surface protein GP is phosphorylated at its ectodomain. Virology 295, 20-29 (2002).
42. M. J. Martínez, N. Biedenkopf, V. Volchkova, B. Hartlieb, N. Alazard-Dany, O. Reynard, S. Becker, V. Volchkov, Role of Ebola virus VP30 in transcription reinitiation. J. Virol. 82, 12569-12573 (2008).
43. K. C. Prins, W. B. Cárdenas, C. F. Basler, Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKe and TBK-1. J. Virol. 83, 3069-3077 (2009).
44. Z. Han, R. N. Harty, Influence of calcium/calmodulin on budding of Ebola VLPs: Implications for the involvement of the Ras/Raf/MEK/ERK pathway. Virus Genes 35, 511-520 (2007).
45. N. Scaplehorn, A. Holmström, V. Moreau, F. Frischknecht, I. Reckmann, M. Way, Grb2 and Nck act cooperatively to promote actin-basedmotility of vaccinia virus. Curr. Biol. 12, 740-745 (2002).
46. T. P. Newsome, I. Weisswange, F. Frischknecht, M.Way, Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus. Cell. Microbiol. 8, 233-241 (2006).
47. M. J. Aman, M. S. Kinch, K. Warfield, T. Warren, A. Yunus, S. Enterlein, E. Stavale, P. Wang, S. Chang, Q. Tang, K. Porter, M. Goldblatt, S. Bavari, Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83, 245-251 (2009).
48. M. S. Kinch, A. S. Yunus, C. Lear, H. Mao, H. Chen, Z. Fesseha, G. Luo, E. A. Nelson, L. Li, Z. Huang, M. Murray, W. Y. Ellis, L. Hensley, J. Christopher-Hennings, G. G. Olinger, M. Goldblatt, FGI-104: A broad-spectrum small molecule inhibitor of viral infection. Am. J. Transl. Res. 1, 87-98 (2009).
49. Y. Liu, R. N. Harty, Viral and host proteins that modulate filovirus budding. Future Virol. 5, 481-491 (2010).
50. P. Ault, Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Clin. J. Oncol. Nurs. 11, 125-129 (2007).
51. R. Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, F. J. Clubb, A. Rosenzweig, R. N. Salomon, R. A. Van Etten, J. Alroy, J. B. Durand, T. Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916 (2006).
52. R. Salie, R. T. Silver, Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 10, 331-335 (2010).
53. H. R. Mellor, A. R. Bell, J. P. Valentin, R. R. A. Roberts, Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-32 (2011).
54. W. P. Kong, C. Hood, Z. Y. Yang, C. J. Wei, L. Xu, A. Garciá-Sastre, T. M. Tumpey, G. J. Nabel, Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U.S.A. 103, 15987-15991 (2006).
55. R. Agami, G. Blandino, M. Oren, Y. Shaul, Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature 399, 809-813 (1999).
56. Z. Y. Yang, Y. Huang, L. Ganesh, K. Leung, W. P. Kong, O. Schwartz, K. Subbarao, G. J. Nabel, pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78, 5642-5650 (2004).
57. L. J. Reed, H. Muench, A simple method of estimating fifty per cent endpoints. Am. J. Hygiene 27, 493-497 (1938).
58. F. Gharahdaghi, C. R. Weinberg, D. A. Meagher, B. S. Imai, S. M. Mische, Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity. Electrophoresis 20, 601-605 (1999).